Skip to main content
Top
Literature
1.
go back to reference Patard J-J, Pouessel D, Bensalah K, Culine S (2008) Targeted therapy in renal cell carcinoma. World J Urol 26:135–140PubMedCrossRef Patard J-J, Pouessel D, Bensalah K, Culine S (2008) Targeted therapy in renal cell carcinoma. World J Urol 26:135–140PubMedCrossRef
2.
go back to reference Escudier B, Koralewski P, Pluzanska A et al (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-{alpha}2a vs placebo/interferon-{alpha}2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25(Suppl):Abstract 3 Escudier B, Koralewski P, Pluzanska A et al (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-{alpha}2a vs placebo/interferon-{alpha}2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25(Suppl):Abstract 3
3.
go back to reference Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRef Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRef
4.
go back to reference Bevacizumab summary of product characteristics, 2008 Bevacizumab summary of product characteristics, 2008
Metadata
Title
Comments on the article “Targeted therapy in renal cell carcinoma” by J.-J. Patard et al.
Author
Bernard Escudier
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 4/2008
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-008-0280-1

Other articles of this Issue 4/2008

World Journal of Urology 4/2008 Go to the issue